Tanvex BioPharma (TPE:6541) LT-Debt-to-Total-Asset : 0.54 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Tanvex BioPharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Tanvex BioPharma's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.54.

Tanvex BioPharma's long-term debt to total assets ratio declined from Dec. 2023 (0.57) to Dec. 2024 (0.54). It may suggest that Tanvex BioPharma is progressively becoming less dependent on debt to grow their business.

Tanvex BioPharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Tanvex BioPharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tanvex BioPharma LT-Debt-to-Total-Asset Chart

Tanvex BioPharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.32

0.35

0.50

0.57

0.54

Tanvex BioPharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.57	0.58	0.46	0.49	0.54

Tanvex BioPharma LT-Debt-to-Total-Asset Calculation

Tanvex BioPharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	1488.224	/	2735.137
	=	0.54

Tanvex BioPharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	1488.224	/	2735.137
	=	0.54

Tanvex BioPharma (TPE:6541) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Tanvex BioPharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Tanvex BioPharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tanvex BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tanvex BioPharma Inc (TPE:6541) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 376, Ren'ai Road, Section 4, 13th Floor-1, Da'an District, Taipei, TWN, 106

Website

https://www.tanvex.com

Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the United States.

Tanvex BioPharma Headlines

No Headlines